How does nivolumab's production take place?

Nivolumab is a monoclonal antibody (mAb) produced by recombinant DNA technology in mammalian cells, then purified and formulated for clinical use. Here’s a high-level overview of how the production typically happens in industry:

- Upstream (cell line development)
- The DNA sequences encoding the nivolumab antibody (heavy and light chains) are inserted into expression vectors.
- The vectors are introduced into a mammalian cell line (usually Chinese hamster ovary, CHO, cells) to create a stable cell line that secretes the antibody.
- A master cell bank is created and then expanded to establish a scalable production line.
- The cells are grown in suspension culture in chemically defined, serum-free media, typically in large bioreactors (fed-batch culture is common).

- Antibody production
- The CHO cells secrete nivolumab into the culture medium.
- Culture conditions are optimized to maximize yield and ensure correct folding and human-like glycosylation.

- Downstream purification (purification and polishing)
- The antibody is captured from the culture supernatant using Protein A affinity chromatography.
- The product is further purified through additional chromatographic steps (e.g., ion exchange, hydrophobic interaction, and/or size-exclusion) to remove contaminants and aggregates.
- Virus inactivation and removal steps (such as low-pH treatment and nanofiltration) are incorporated for safety.
- The product is buffer-exchanged and concentrated to the desired formulation.

- Formulation and fill-finish
- The purified antibody is formulated in a stable buffer, sterile-filtered, and filled into vials or pre-filled syringes under aseptic conditions.
- The final product is boxed and labeled for distribution.

- Quality control and regulatory compliance
- Extensive testing ensures identity, purity, potency (binding to PD-1), safety (endotoxin levels, sterility, lack of contaminants), and consistent glycosylation.
- All steps follow Good Manufacturing Practice (GMP) and regulatory requirements; some details are proprietary to the manufacturer.

Notes:
- Nivolumab is an IgG4 antibody with a hinge modification (S228P) to improve stability and reduce unwanted half-molecule exchange and effector functions.
- While the general workflow is common to many therapeutic antibodies, exact process conditions, scales, and purification steps are proprietary and can vary between manufacturing sites.

If you’d like, I can tailor this to a particular part of the process (upstream cell culture, purification steps, or quality control) or provide a simplified diagram-style summary.